Pharma giant Pfizer is injecting $600 million into its venture investment arm in a bid to ramp up its involvement in biotechnology and other emerging growth companies.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS